Abstract
Background: Hypertension (HTN) is a common side effect of tacrolimus (Tac), the first-line antirejection medication for kidney transplant recipients. The impact of immediate-release tacrolimus (Tac IR) dosed twice daily versus extended-release tacrolimus (Tac ER) dosed once daily on long-term blood pressure control in kidney transplant recipients remains understudied. This study aims to compare the use of Tac IR versus Tac ER in kidney transplant recipients and evaluate the effects of the different formulations on systolic blood pressure (SBP), diastolic blood pressure (DBP), and HTN crisis. Methods: This retrospective cohort study at a single institution collected baseline characteristics, time-varying exposure to Tac IR versus Tac ER, SBP, DBP, HTN crisis, and confounders at each posttransplant visit. A marginal structural linear mixed-effects model was employed to analyze the longitudinal blood pressure control in kidney transplant recipients receiving Tac IR and Tac ER. Results: The final analysis included 654 patients, with mean ages of 52.0 years for Tac IR and 50.3 years for Tac ER. Males constituted 56.7% in Tac IR and 55.0% in Tac ER. Notably, the black population had 2.44 times higher odds of receiving Tac ER after adjusting for the rest of the baseline characteristics. No difference was found between longitudinal SBP (p = 0.386, 95% CI: −1.00, 2.57) or DBP (p = 0.797, 95% CI: −1.38, 1.06). Conclusion: Our study indicates that posttransplant patients taking Tac ER exhibit no difference in chronic SBP and DBP controls compared to Tac IR.
Journal Section:
Clinical Practice: Research Article
References
1.
Yu
M
, Liu
M
, Zhang
W
, Ming
Y
. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation
. Curr Drug Metab
. 2018
;19
(6
):513
–22
. 2.
Gardiner
KM
, Tett
SE
, Staatz
CE
. Multinational evaluation of mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus utilization
. Ann Transplant
. 2016
;21
:1
–11
. 3.
Trofe-Clark
J
, Brennan
DC
, West-Thielke
P
, Milone
MC
, Lim
MA
, Neubauer
R
, et al. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American, kidney transplant recipients
. Am J Kidney Dis
. 2018
;71
(3
):315
–26
. 4.
Langone
A
, Steinberg
SM
, Gedaly
R
, Chan
LK
, Shah
T
, Sethi
KD
, et al. Switching study of kidney transplant patients with tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study
. Clin Transplant
. 2015
;29
(9
):796
–805
. 5.
Georgianos
PI
, Vaios
V
, Sgouropoulou
V
, Eleftheriadis
T
, Tsalikakis
DG
, Liakopoulos
V
. Hypertension in dialysis patients: diagnostic approaches and evaluation of epidemiology
. Diagnostics
. 2022
;12
(12
):2961
. 6.
Lewington
S
, Clarke
R
, Qizilbash
N
, Peto
R
, Collins
R
; Prospective Studies Collaboration
. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
. Lancet
. 2002
;360
(9349
):1903
–13
. 7.
Mange
KC
, Cizman
B
, Joffe
M
, Feldman
HI
. Arterial hypertension and renal allograft survival
. JAMA
. 2000
;283
(5
):633
–8
. 8.
Kasiske
BL
, Anjum
S
, Shah
R
, Skogen
J
, Kandaswamy
C
, Danielson
B
, et al. Hypertension after kidney transplantation
. Am J Kidney Dis
. 2004
;43
(6
):1071
–81
. 9.
Didion
SP
. Tacrolimus-induced hypertension: what’s endothelial and hematopoetic FKBP12 got to do with it
. Hypertension
. 2011
;57
(6
):1058
–60
. 10.
Schrader
LI
, Kinzenbaw
DA
, Johnson
AW
, Faraci
FM
, Didion
SP
. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy
. Arterioscler Thromb Vasc Biol
. 2007
;27
(12
):2576
–81
. 11.
Madhur
MS
, Lob
HE
, McCann
LA
, Iwakura
Y
, Blinder
Y
, Guzik
TJ
, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction
. Hypertension
. 2010
;55
(2
):500
–7
. 12.
Rostaing
L
, Bunnapradist
S
, Grinyó
JM
, Ciechanowski
K
, Denny
JE
, Silva
HT
, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial
. Am J Kidney Dis
. 2016
;67
(4
):648
–59
. 13.
January
SE
, Hagopian
JC
, Nesselhauf
NM
, Progar
K
, Horwedel
TA
, Santos
RD
. Clinical experience with extended-release tacrolimus in older adult kidney transplant recipients: a retrospective cohort study
. Drugs Aging
. 2021
;38
(5
):397
–406
. 14.
Charlson
ME
, Pompei
P
, Ales
KL
, MacKenzie
CR
. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
. J Chronic Dis
. 1987
;40
(5
):373
–83
. 15.
Quan
H
, Li
B
, Couris
CM
, Fushimi
K
, Graham
P
, Hider
P
, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries
. Am J Epidemiol
. 2011
;173
:676
–82
. 16.
Levine
MA
, Schuler
T
, Gourishankar
S
. Complications in the 90-day postoperative period following kidney transplant and the relationship of the Charlson comorbidity index
. Can Urol Assoc J
. 2017
;11
(12
):388
–93
. 17.
Levy
PD
, Willock
RJ
, Burla
M
, Brody
A
, Mahn
J
, Marinica
A
, et al. Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction
. J Am Soc Hypertens
. 2016
;10
(12
):906
–16
. 18.
Islam
MS
. Hypertension: from basic research to clinical practice
. Adv Exp Med Biol
. 2017
;956
:1
–2
. 19.
Robins
JM
, Hernan
MA
, Brumback
B
. Marginal structural models and causal inference in epidemiology
. Epidemiology
. 2000
;11
(5
):550
–60
. 20.
Budde
K
, Rostaing
L
, Maggiore
U
, Piotti
G
, Surace
D
, Geraci
S
, et al. Prolonged-release once-daily formulation of tacrolimus versus standard-of-care tacrolimus in de novo kidney transplant patients across Europe
. Transpl Int
. 2022
;35
(35
):10225
. 21.
Gaber
AO
, Alloway
RR
, Bodziak
K
, Kaplan
B
, Bunnapradist
S
. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients
. Transplantation
. 2013
;96
(2
):191
–7
. 22.
Huppertz
A
, Bollmann
J
, Behnisch
R
, Bruckner
T
, Zorn
M
, Burhenne
J
, et al. Differential effect of a continental breakfast on tacrolimus formulations with different release characteristics
. Clin Pharmacol Drug Dev
. 2021
;10
(8
):899
–907
. 23.
Francke
MI
, Hesselink
DA
, Li
Y
, Koch
BCP
, de Wit
LEA
, van Schaik
RHN
, et al. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
. Br J Clin Pharmacol
. 2021
;87
(4
):1918
–29
. 24.
Parati
G
, Stergiou
GS
, Dolan
E
, Bilo
G
. Blood pressure variability: clinical relevance and application
. J Clin Hypertens
. 2018
;20
(7
):1133
–7
. 25.
Louis
ED
, Barnes
LF
, Ford
B
, Pullman
SL
, Yu
Q
. Ethnic differences in essential tremor
. Arch Neurol
. 2000
;57
(5
):723
–7
. 26.
Tang
JT
, Andrews
LM
, van Gelder
T
, Shi
Y
, van Schaik
RHN
, Wang
LL
, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations
. Expert Opin Drug Metab Toxicol
. 2016
;12
(5
):555
–65
. 27.
Sanghavi
K
, Brundage
R
, Miller
M
, Schladt
D
, Israni
A
, Guan
W
, et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients
. Pharmacogenomics J
. 2017
;17
(1
):61
–8
. 28.
Cosio
FG
, Pelletier
RP
, Pesavento
TE
, Henry
ML
, Ferguson
RM
, Mitchell
L
, et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients
. Kidney Int
. 2001
;59
(3
):1158
–64
. 29.
Cosio
FG
, Pelletier
RP
, Sedmak
DD
, Pesavento
TE
, Henry
ML
, Ferguson
RM
. Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology
. Kidney Int
. 1999
;56
(5
):1912
–9
. 30.
Carretero
A
, Oparil
S
. Essential hypertension. Part I: definition and etiology
. Circulation
. 2000
;101
(3
):329
–35
. 31.
Hoorn
EJ
, Ellison
DH
. Diuretic resistance
. Am J Kidney Dis
. 2017
;69
(1
):136
–42
. 32.
Pioli
MR
, Ritter
AMV
, de Faria
AP
, Modolo
R
. White coat syndrome and its variations: differences and clinical impact
. Integr Blood Press Control
. 2018
;11
:73
–9
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
